更新于：2024-12-21

Danazol

达那唑

更新于：2024-12-21

概要

概要

基本信息

药物类型

小分子化药

别名

Danazol (JP17/USP/INN)、Danazol Suppositories、Optina

+ [12]

靶点

作用机制

AR激动剂(雄激素受体激动剂)

治疗领域

免疫系统疾病心血管疾病遗传病与畸形+ [5]

在研适应症

乳腺疾病子宫内膜异位症纤维囊性乳腺疾病+ [5]

非在研适应症

糖尿病性黄斑水肿乳痛症

原研机构

Sanofi

在研机构

江苏联环药业股份有限公司

Mitsubishi Tanabe Pharma Corp.

非在研机构

FemmePharma Global Healthcare, Inc.

Sanofi-Aventis U.S. LLC

Ampio Pharmaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1976-06-21),

子宫内膜异位症纤维囊性乳腺疾病遗传性血管性水肿

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C22H27NO2

InChIKeyPOZRVZJJTULAOH-LHZXLZLDSA-N

CAS号17230-88-5

关联

项与达那唑相关的临床试验

NCT06176911 / Recruiting临床2期IIT

A Multicenter, Open-label, Randomized, Controlled, Phase 2 Trial Comparing the Efficacy and Safety of Teriflunomide Plus Danazol in Patients With Steroid-resistant/Relapse ITP

To compare the efficacy and safety of teriflunomide plus danazol versus danazol in patients with steroid-resistant/relapse ITP

开始日期2023-12-05

申办/合作机构

北京大学人民医院

[+9]

NCT05852847 / Recruiting临床2期IIT

Low-dose Baricitinib Plus Danazol Versus Danazol for Patients With Steroid-resistant/Relapse Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Phase 2 Trial

This is a prospective, multicenter, randomized, controlled phase 2 trial to compare the efficacy and safety profiles in ITP patients receiving baricitinib plus danazol to those receiving danazol alone.

开始日期2023-05-16

申办/合作机构

北京大学人民医院

[+9]

NCT04873102 / Recruiting临床2期IIT

A Phase II Single Center Single Arm Pilot Study Administering Danazol for Treatment of Cytopenias in Patients With Cirrhosis

This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months. The goal will be to treat a total of 10 patients.

开始日期2023-05-01

申办/合作机构

University of Southern California

100 项与达那唑相关的临床结果

登录后查看更多信息

100 项与达那唑相关的转化医学

登录后查看更多信息

100 项与达那唑相关的专利（医药）

登录后查看更多信息

2,587

项与达那唑相关的文献（医药）

2024-12-01·STEROIDS

Palladium catalysed cross coupling reactions on 2,3-isoxazol-17α-ethynyltestosterone, their anti-cancer activity, molecular docking studies and ADMET analysis

Article

作者: Yadav, Astha ; Srivastava, Sanjay ; Verma, Anmol ; Pratap Singh, Ranvijay ; Sethi, Arun ; Prakash, Rohit ; Singh, Saurabh Kumar

In the current study, the Sonogashira coupling reaction of danazol with aryl halides was carried out, yielding new aryl substituted danazol derivatives. The synthetic compounds were examined for anti-cancer potential on the HeLa human cervical cancer cell line, and they showed promising cytotoxic action. Synthesized compounds 2, 4 and 5 inhibited the growth of HeLa cervical cancer cells, potentially making them effective anti-cancer drugs in the future. Furthermore, molecular docking studies were performed to evaluate the inhibitory impact of danazol derivatives on the Human Papillomavirus (HPV) target protein (1F9F). The docking results showed a significant inhibitory action against the cervical cancer protein (1F9F). The binding energy (ΔG) values of 1, 2, 3, 4 and 5 against the protein 1F9F were -8.01, -8.70, -9.43, -9.58 and -9.75 kcal/mol, indicating a high affinity of the synthesized compounds to bind with the HPV target proteins compared to their parent compound danazol (1). ADMET analyses of all derivatives have also been carried out.

2024-12-01·Journal of computer-aided molecular design

Molecular dynamics study on micelle-small molecule interactions: developing a strategy for an extensive comparison

Article

作者: Larsson, Per ; Kabedev, Aleksei ; Bergström, Christel A S

Abstract:

Theoretical predictions of the solubilizing capacity of micelles and vesicles present in intestinal fluid are important for the development of new delivery techniques and bioavailability improvement. A balance between accuracy and computational cost is a key factor for an extensive study of numerous compounds in diverse environments. In this study, we aimed to determine an optimal molecular dynamics (MD) protocol to evaluate small-molecule interactions with micelles composed of bile salts and phospholipids. MD simulations were used to produce free energy profiles for three drug molecules (danazol, probucol, and prednisolone) and one surfactant molecule (sodium caprate) as a function of the distance from the colloid center of mass. To address the challenges associated with such tasks, we compared different simulation setups, including freely assembled colloids versus pre-organized spherical micelles, full free energy profiles versus only a few points of interest, and a coarse-grained model versus an all-atom model. Our findings demonstrate that combining these techniques is advantageous for achieving optimal performance and accuracy when evaluating the solubilization capacity of micelles.Graphical abstractAll-atom (AA) and coarse-grained (CG) umbrella sampling (US) simulations and point-wise free energy (FE) calculations were compared to their efficiency to computationally analyze the solubilization of active pharmaceutical ingredients in intestinal fluid colloids.

2024-12-01·Journal of Allergy and Clinical Immunology-In Practice

Angioedema due to Acquired C1-Inhibitor Deficiency Associated With Monoclonal Gammopathies of Undetermined Significance Characteristics of a French National Cohort

Article

作者: Cathebras, Pascal ; Gayet, Stephane ; Pelletier, Fabien ; Coppo, Paul ; McAvoy, Chloé ; Ly, Kim Heang ; Hadjadj, Jerome ; Martin, Ludovic ; Blaison, Gilles ; Caubet, Olivier ; Boccon-Gibod, Isabelle ; Kanny, Gisele ; Kalmi, Galith ; Defendi, Federica ; Aubineau, Magali ; Desblache, Julien ; Brihaye, Benoit ; Bibes, Beatrice ; Amarger, Stephanie ; Bouillet, Laurence ; Fain, Olivier ; Lacoste, Marion ; Mekinian, Arsene ; Demoreuil, Claire ; Durupt, Francois ; Gobert, Delphine ; Gondran, Guillaume ; Launay, David ; Robbins, Aylsa ; Ollivier, Yann ; Adamski, Henri ; Roos-Weil, Damien ; Armengol, Guillaume ; Blanchard-Delaunay, Claire ; Lahuna, Constance

BACKGROUND:

No specific description of monoclonal gammopathies of undetermined significance (MGUS)-associated angioedema due to acquired C1 inhibitor deficiency (AAE-C1-INH) has been reported yet.

OBJECTIVE:

To describe the biological and clinical characteristics, evolution, and response to treatment of MGUS-associated AAE-C1-INH.

MATERIALS AND METHODS:

We conducted a French national retrospective observational study on MGUS-associated acquired angioedema spanning a 30-year period.

RESULTS:

Forty-one patients with MGUS-associated AAE-C1-INH at diagnosis were included; 68% displayed anti-C1-INH antibodies. The monoclonal component was an IgM in 24 patients, IgG in 11, and IgA in 6 patients. The mean age at first angioedema attack was 63 years (standard deviation [SD] = 13 years) and at diagnosis 66 years (SD = 11 years). A total of 88% patients benefited from acute attack treatments, and 77% from long-term prophylaxis, either danazol, tranexamic acid, or lanadelumab. Median follow-up was 7 years, during which 14 patients (33%) evolved into well-defined malignant hemopathies. Fifty percent of patients were given a hematological treatment, either rituximab alone, indicated by recurrent attacks of angioedema in patients with AAE-C1-INH with anti-C1-INH antibodies, or validated combinations of chemotherapies, indicated by evolution into a lymphoma in 7 patients and a myeloma in 3 patients. Fifteen patients (35%) were in clinical complete remission of angioedema at last visit, of whom 60% had an undetectable serum monoclonal immunoglobulin.

CONCLUSIONS:

Complete remission of AAE-C1-INH is correlated to complete remission of the underlying hematological malignancy, as defined by an undetectable serum monoclonal immunoglobulin. In our MGUS-associated acquired angioedema cohort, we recorded an incidence of evolution into hematological malignancy of 4% per patient-year. It is therefore crucial to conduct full hematological workup during follow-up at an annual rate, and earlier if AAE relapses or if acute attack frequency increases.

项与达那唑相关的新闻（医药）

2024-11-13

·Pharmaceutical Technology

Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health Canada has granted approval for GlaxoSmithKline’s ( GSK ) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is indicated for use in patients with intermediate or high-risk primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF. This approval is based on the results from the global, randomised, multicentre, double-blind Phase III MOMENTUM trial of Ojjaara. The trial compared momelotinib with danazol in symptomatic and anaemic MF patients who had previously received treatment with an approved Janus kinase inhibitor. It assessed the safety and efficacy of momelotinib in addressing various aspects of the disease, including symptom relief, reduction in blood transfusions required for anaemia, and decrease in spleen enlargement. According to the trial’s findings, Ojjaara treatment offered improvements in total symptom score, transfusion independence, and splenic response rate. The approval in Canada is also backed by further data from a patient subset in the Phase III SIMPLIFY-1 trial, which demonstrated Ojjaara’s efficacy in treating MF patients with moderate-to-severe anaemia and related symptoms. In September last year, the US Food and Drug Administration approved Ojjaara for the same indication. Initially developed by Sierra Oncology , GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. GSK Canada interim country medical director Michelle Horn said: “Treatment options for myelofibrosis-related anaemia have been limited. We are proud to offer this treatment alternative for Canadian patients to address this critical unmet need and other myelofibrosis symptoms. “With most myelofibrosis patients becoming anaemic over time, Ojjaara’s approval represents a significant milestone to improve the outcomes of these patients while also highlighting GSK’s commitment to making an impact in Canada’s haematology oncology space through innovative new treatments.”

临床3期上市批准并购临床结果生物类似药

2024-07-26

·药融云

吉利德长效HIV疗法lenacapavir预防有效率100%！博瑞医药、合源生物新药数据登上顶刊

来源：药融云新药笔记，更多新药内容点击上方名片☝︎关注药融云新药笔记。 1.吉利德长效HIV疗法lenacapavir登《新英格兰医学杂志》，每半年注射一次，100%有效！ 7月25日，吉利德科学（Gilead Sciences）公布其关键3期PURPOSE 1试验的中期分析详细结果。该公司每半年注射一次的艾滋病毒（HIV）衣壳抑制剂lenacapavir在女性中的HIV预防用途上显示出100%的有效性，相比于每日一次口服疗法以及HIV的背景发病率皆表现出显著的优效性。据此积极结果，独立数据监测委员会建议吉利德提早解盲，并提供所有受试者开放标签的lenacapavir。该试验的详细结果也同步刊登于《新英格兰医学杂志》（NEJM）当中。PURPOSE 1 是一项 3 期、双盲、随机的非劣性研究，旨在评估每半年一次皮下注射 Lenacapavir 进行暴露前预防 (PrEP) 和每日一次口服 Truvada（舒发泰®，emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF）或 Descovy（达可挥®，emtricitabine 200mg and tenofovir alafenamide 25mg; F/TAF）对 16～25 岁女性和青春期女孩的安全性和有效性的优劣。研究共纳入来自南非 25 个地点和乌干达 3 个地点的5300 多名 16～25 岁女性和青春期女孩。参与者按照 2:2:1 的比例随机分配到三组，一组每半年注射一次 Lenacapavir，一组接受每日一次口服 Descovy，另一组每日一次口服 Truvada。结果显示，在 Lenacapavir 组的 2134 名女性中，HIV 感染病例为 0（incidence 0.00 per 100 person-years）；在 Truvada 组 1068 名女性中， HIV 感染病例为 16 例（incidence 1.69 per 100 person-years）。每半年一次的 Lenacapavir 优于 bHIV（incidence 2.41 per 100 person-years）和Truvada，同时达到主要终点和次要终点（两个终点的 p<0.0001）。Lenacapavir（商品名Sunlenca）是一种“first-in-class”长效HIV衣壳抑制剂，可以干扰HIV病毒衣壳蛋白的组装和拆卸，在HIV-1生命周期的多个阶段发挥作用，一旦获批，将成为首款每年仅需使用两次的HIV暴露前预防（PrEP）疗法。 2.博瑞医药GLP-1R/GIPR激动剂BGM0504临床前结果在Nature子刊发表 7月19日，来自博瑞医药及武汉理工大学的研究团队在Nature子刊Scientific Reports杂志上报道了一款AI辅助设计的新型GLP-1R/GIPR双重激动剂BGM0504的临床前研究结果。BGM0504独特的分子设计导致其激动活性相比替尔泊肽增加了2-3倍。在糖尿病和NASH小鼠模型中，BGM0504也显示出了优于替尔泊肽的治疗效果。GIPR和GLP-1R作为调节糖脂和氨基酸代谢的B1类G蛋白偶联受体，是2型糖尿病和肥胖症潜在的治疗靶标。BGM0504注射液是一款GLP-1和GIP受体双重激动剂，可激动GIP和GLP-1下游通路，产生控制血糖、减重和治疗非酒精性脂肪性肝炎（NASH）等生物学效应，展现多种代谢疾病治疗潜力。BGM0504是国内第2款同时获批2-型糖尿病及超重或肥胖症临床试验的GIPR/GLP-1R激动剂。在最新发表的这项研究中，来自博瑞医药的研究团队与合作伙伴采用分子动力学模拟的方法，设计了一种新型GLP-1R/GIPR双激动剂BGM0504。MMGBSA计算显示，BGM0504对GLP-1R和GIPR的结合亲和力均强于替尔泊肽。此外，研究也证实，相比未酰化的母肽，BGM0504对GLP-1R和GIPR均表现出有竞争性的结合亲和力。在2型糖尿病模型db/db小鼠体内实验评估中，BGM0504在初始给药后显著降低了非空腹血糖，超过了替尔泊肽在同等剂量下的疗效。肝纤维化是NASH发病机制的一个标志，NASH模型组小鼠始终表现出稳定的纤维化。该研究同时评估了BGM0504和替尔泊肽对肝组织纤维化的影响，并发现与模型组相比，BGM0504各剂量组纤维化率均显著降低。 3.Viking：GLP-1R/GIPR激动剂VK2735跳过2b期直接挺进3期，减重效果显著！ 7月24日，Viking Therapeutics 在2024二季度业绩报告中透露：其GLP-1R/GIPR激动剂VK2735将跳过2b期临床试验，直接挺进3期减重临床。并表示，该项决定是基于近期收到的Type C meeting 之后FDA 的书面反馈，并计划于下半年和 FDA 召开End-of-Phase Meeting。今年2月28日，Viking Therapeutics宣布其在研小分子激动剂VK2735于2期临床试验VENTURE治疗肥胖患者的积极顶线结果。分析显示，每周接受一次15 mg VK2735治疗的患者在13周后其平均体重较基线下降达14.7%（14.6公斤，即约29.2斤），具统计学意义。此外，与安慰剂相比，接受VK2735治疗的患者平均体重亦显著下降高达13.1%。与基线和安慰剂相比，从第一周开始一直持续到整个13周治疗期间，使用所有剂量VK2735的患者其体重均观察到具统计学上的显著差异。患者在整个研究过程中，体重逐渐下降，且在第13周时未观察到体重减轻幅度达到平台期。在评估体重减轻至少10%患者比例的关键次要终点上，使用所有剂量VK2735患者与安慰剂相比也显示出统计学上的显著差异。VK2735治疗组中高达88%的患者体重减轻≥10%，而安慰剂组在此数值上仅为4%。受此消息影响，Viking Therapeutics股价盘后大涨20%，市值超过67亿美元。 4.艾伯维靶向SEZ6创新ADC ABBV-706在华申报临床，针对肺癌等 7月25日，中国国家药监局药品审评中心（CDE）官网公示，艾伯维（AbbVie）申报的ABBV-706注射用冻干粉临床试验申请获得受理。ABBV-706是一种靶向SEZ6的抗体偶联药物（ADC），有效载荷为TOP1i，目前正在国际范围内处于1期临床研究阶段（NCT05599984）。此次是这款SEZ6靶向ADC在研产品首次在中国申报临床。癫痫相关同源物 6 (SEZ6)是在选定神经元谱系细胞的细胞表面上发现的跨膜蛋白。通过 mRNA 表达分析和 IHC，SEZ6是 SCLC 中高表达的表面标志物，而在正常组织中表达有限，这一特性使其成为ADC 药物的理想靶标。在2024 ASCO年会上，艾伯维以口头报告的形式公布了ABBV-706的首次人体研究的单药剂量递增部分的早期数据。数据显示，在总共48名可评估疗效的患者（23 名 SCLC 和 25 名 NEN）中，总体确认的客观缓解率为43.8%。在SCLC组中，确认的客观缓解率为 60.9%。在数据截止时，在所有53名入组患者中，最常见的≥3 TEAE是中性粒细胞减少症（42%）、贫血症（42%）和白细胞减少症（28%）。目前ABBV-706正在开展1期临床试验，评估ABBV-706作为单一疗法或与Budigalimab（ABBV-181）、卡铂或顺铂联合用于治疗晚期实体瘤患者。 5.海思科1类新药HSK39004获批临床，针对慢性阻塞性肺疾病 7月25日，中国国家药监局药品审评中心（CDE）官网公示，海思科申报的1类新药HSK39004吸入混悬液的两项临床试验申请获得批准，拟用于慢性阻塞性肺疾病（COPD）的治疗。这是海思科药业在呼吸疾病治疗领域又一款迈入临床阶段的在研新药。创新药HSK39004是海思科自主研发的全新的具有独立知识产权的靶向小分子抑制剂，临床拟用于气道阻力为特征的阻塞性肺病（如COPD、哮喘）的治疗。临床前研究结果显示，HSK39004在离体气管环和体内疾病模型中表现出显著的气道舒张和抗炎作用，且安全性良好，是一款极具开发潜力的小分子阻塞性肺病治疗药物，有望为COPD、哮喘等阻塞性肺病患者提供一种新的治疗选择。慢性阻塞性肺病（COPD）主要影响人体的支气管和肺泡。与口服或注射等全身性给药方式相比，吸入给药因其能够与呼吸系统的生理和组织结构相得益彰，已成为国内外权威指南推崇的首选治疗COPD的给药方式。HSK39004吸入混悬液有望给患者带来新的治疗选择。 6.合源生物靶向CD19 CAT-T产品纳基奥仑赛研究成果在《新英格兰医学杂志》发表 7月25日，合源生物宣布，国际顶级期刊《新英格兰医学杂志》 (NEJM）在线发表了靶向CD19嵌合抗原受体自体T（CD19 CAR-T）细胞注射液（纳基奥仑赛注射液）治疗系统性红斑狼疮相关免疫性血小板减少症（SLE-ITP）的研究论文。该报道展现了CAR-T（纳基奥仑赛）治疗在SLE-ITP中良好并持久的疗效和安全性，显示了CAR-T在SLE及ITP治疗中的应用潜力。系统性红斑狼疮（SLE）是一种慢性系统性自身免疫性疾病，常导致全身多器官损害，B细胞异常及自身抗体产生在其发病中起到至关重要的作用。SLE可引起免疫性血小板减少，在中国SLE患者中占16%，其中相当一部分患者对糖皮质激素、免疫抑制剂和生物制剂均反应不佳，此类患者预后不佳，长期存在重要脏器出血风险，是SLE治疗中的一大难点。该文章报道一例女性患者，于2014年确诊系统性红斑狼疮，存在持续性重度免疫性血小板减少症。该患者既往接受甲泼尼龙冲击、羟氯喹、静脉注射免疫球蛋白、他克莫司、环孢素、西罗莫司、利妥昔单抗、达那唑、艾曲波帕和促血小板生成素治疗均无效，血小板计数始终处于20×109/L以下，并伴有皮肤黏膜出血表现。该患者于2023年9月接受自体CD19 CAR-T（纳基奥仑赛）细胞一次回输并持续随访。患者治疗疗效：纳基奥仑赛注射液回输后CAR-T细胞在患者体内扩增良好，回输第28天血液中CD19阳性B细胞被清除，第三个月时B细胞重建。血小板计数治疗后的六个月内持续上升，由4×109/L上升到第一个月时的29×109/L ，第三个月75×109/L，第六个月109×109/L，达到临床完全缓解，且患者停用了糖皮质激素和所有免疫抑制剂。患者抗核抗体滴度也明显下降。 END 近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“CSCO”，获取2023CSCO指南后台回复关键词“ASCO”，获取2023ASCO分癌种摘要后台回复关键词“2022首仿”，获取2022年首仿药物获批名单后台回复关键词“医保”，获取2022年医保目录联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

临床结果临床3期

2024-07-25

·同写意

全球首例！合源生物纳基奥仑赛治疗难治性系统性红斑狼疮相关免疫性血小板减少症（SLE-ITP）的研究成果在《新英格兰医学杂志》发表

免疫疗法细胞疗法临床研究

100 项与达那唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00289	达那唑	G03XA01	DB01406

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
乳腺疾病	日本	Mitsubishi Tanabe Pharma Corp.	1995-08-18
男子乳腺发育	中国	江苏联环药业股份有限公司	1985-01-01
性早熟	中国	江苏联环药业股份有限公司	1985-01-01
免疫性血小板减少症	中国	江苏联环药业股份有限公司	1985-01-01
系统性红斑狼疮	中国	江苏联环药业股份有限公司	1985-01-01
子宫内膜异位症	美国	Sanofi-Aventis U.S. LLC	1976-06-21
纤维囊性乳腺疾病	美国	Sanofi-Aventis U.S. LLC	1976-06-21
遗传性血管性水肿	美国	Sanofi-Aventis U.S. LLC	1976-06-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病性黄斑水肿	临床3期	美国	Ampio Pharmaceuticals, Inc.	2013-02-01
乳痛症	临床2期	美国	FemmePharma Global Healthcare, Inc.	2010-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	端粒病	-	Danazol 800mg	選蓋獵膚鬱餘觸製網鏇(獵蓋餘顧構鬱遞糧積衊) = 鹹蓋壓築顧鬱簾鬱遞願製鹹蓋艱顧衊鑰鬱窪廠 (膚顧網廠衊鏇壓鏇鬱壓 ) 更多	-	2024-12-08
NCT00953771 (ASH2023)	临床2期	血栓性血小板减少性紫癜	9	Danazol (Experimental Group (EG))	選衊鹽糧願選範網壓窪(製選選願構窪製鑰網獵) = One episode of hypotension occurred in EG, for which treatment was not discontinued 醖糧憲範蓋餘膚夢膚選 (簾觸鹹鏇艱糧鹽糧築簾 ) 更多	-	2023-12-11
				Danazol (Historical controls (HC))
NCT01821677 (CTgov)	临床2期	糖尿病性黄斑水肿	354	Danazol Capsules (Low Dose Danazol)	蓋鏇淵壓襯鹽築鬱構鏇(鬱蓋艱蓋築遞鑰鑰膚齋) = 鬱繭蓋鹽願積蓋製願齋選餘構製夢餘觸蓋範襯 (選蓋醖簾淵網淵淵觸壓, 艱繭齋網蓋齋淵憲繭襯 ~ 鹹憲鬱顧製齋製衊襯鹹) 更多	-	2022-10-10
				Danazol Capsules (High Dose Danazol)	蓋鏇淵壓襯鹽築鬱構鏇(鬱蓋艱蓋築遞鑰鑰膚齋) = 遞鬱襯醖製壓齋壓齋獵選餘構製夢餘觸蓋範襯 (選蓋醖簾淵網淵淵觸壓, 蓋壓簾製夢廠獵鬱構窪 ~ 醖願齋鹹積簾艱齋壓廠) 更多
NCT03909763 (CTgov)	临床2期	免疫性血小板减少症	55	Berberine+danazol	夢鑰鹽廠選艱夢餘網製(製鬱願膚襯糧鹽鹹選鑰) = 遞鬱鹹繭獵窪憲選選簾鏇鏇鹽願鏇蓋鏇壓構觸 (衊範齋積齋鏇膚範鹽艱, 齋製衊淵鹽觸襯蓋繭鏇 ~ 網餘蓋選糧鬱夢壓淵鑰) 更多	-	2020-09-25
NCT01441037 (CTgov)	临床1/2期	再生障碍性贫血	27	Danazol	襯憲鬱廠構觸襯醖蓋構(餘齋觸網壓願齋壓壓簾) = 蓋製範壓壓積構餘鏇窪觸網淵範願範蓋餘選鹽 (遞壓構夢餘廠夢糧顧願, 築淵襯淵鏇衊繭獵醖範 ~ 獵顧壓觸繭選窪願壓願) 更多	-	2018-07-11
NCT01732445 (CTgov)	临床2期	贫血 \| 原发性血小板增多症后骨髓纤维化 \| 真性红细胞增多症后骨髓纤维化 ... 更多	14	questionnaire administration+ruxolitinib phosphate+danazol	鹹壓構網願餘膚簾淵繭(醖憲襯積鬱廠鹽顧選壓) = 膚願網淵艱觸繭積簾範網憲醖築獵顧範顧遞製 (淵鏇艱繭選繭鹽襯糧繭, 廠鏇積鬱鏇衊顧積糧遞 ~ 齋鹹構顧餘顧壓餘觸蓋) 更多	-	2017-10-18
EHA2017	N/A	再生障碍性贫血 \| 骨髓增生异常综合征	31	Danazol 600 mg	鬱構窪鏇積淵齋壓衊淵(積艱顧鏇糧鑰遞衊艱願) = 3 G1, 1 G2, 3 G3 鏇淵顧簾顧網獵選淵築 (積夢鬱鏇簾願鹹窪餘鏇 ) 更多	积极	2017-05-18
				Danazol 400 mg
NCT01441037 (Pubmed \| N Engl J Med)	临床1/2期	-	27	Danazol	淵範蓋襯餘艱醖窪鹹遞(襯觸鑰衊觸壓壓構選衊) = 醖獵齋獵鏇鹹壓願構製願醖餘糧製積糧遞製鏇 (糧鹽鑰淵窪鹹構鑰憲簾 ) 更多	-	2016-05-19
ARVO2016	临床3期	糖尿病性黄斑水肿	425	Placebo	窪簾鑰艱範艱積夢艱鹽(鹽襯衊鑰糧憲蓋築遞遞) = 築獵膚壓壓積鬱鏇窪選醖糧壓壓選遞願製積壓 (鑰襯醖願窪鑰顧艱窪壓 )	积极	2016-05-01
				0.5mg danazol/BMI	窪簾鑰艱範艱積夢艱鹽(鹽襯衊鑰糧憲蓋築遞遞) = 鑰鹹鹹餘壓壓醖憲餘網醖糧壓壓選遞願製積壓 (鑰襯醖願窪鑰顧艱窪壓 )
AAAAI2006	N/A	遗传性血管性水肿	23	Danazol	範窪選艱淵選憲憲衊鑰(窪鏇觸膚淵製顧鏇齋餘) = 艱襯繭範簾夢淵遞蓋憲構夢鬱簾淵壓願網襯網 (餘齋襯鹽鏇鏇鏇鏇夢艱 )	积极	2006-02-01
				C1-INH	範窪選艱淵選憲憲衊鑰(窪鏇觸膚淵製顧鏇齋餘) = 製鏇齋鹽願選齋繭夢願構夢鬱簾淵壓願網襯網 (餘齋襯鹽鏇鏇鏇鏇夢艱 )